Draper’s Millions: The Philanthropic Wellspring of Modern Race Science
By Angela Saini,
Undark
| 12. 16. 2022
In 1961, a new journal of ethnology and anthropology appeared on academic bookshelves. Nearly every page betrayed an obsession with racial differences.
“The few worthwhile contributions cannot justify the publication of the rest of the journal,” wrote the English anthropologist G. Ainsworth Harrison, spotting error after error. “None of the authors rigorously and objectively appraises the limitations of the tests he uses.” One article made the bizarre claim that Egypt — a country described as being made up of racial “hybrids” — was more “disease-ridden” as a result. “What is particularly insidious in a supposedly scientific journal is the use of words with overtones of moral judgment,” Harrison concluded.
What he didn’t know was that this was entirely by design. The journal had been founded by a tight web of far-right thinkers intent on blocking racial integration in the United States, ending immigration from everywhere but Western Europe, and promoting eugenic policies that would encourage only those they believed were the fittest to survive and reproduce. They were relying on the naivete of fellow researchers, using academia as cover so...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi, MIT Technology Review | 03.25.2025
Why do we hear about medical breakthroughs in mice, but rarely see them translate into cures for human disease? Why do so few drugs that enter clinical trials receive regulatory approval? And why is the waiting list for organ transplantation...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...